Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
24.97
-0.19 (-0.76%)
At close: Dec 26, 2025, 4:00 PM EST
24.82
-0.15 (-0.60%)
After-hours: Dec 26, 2025, 5:00 PM EST
Apellis Pharmaceuticals Revenue
Apellis Pharmaceuticals had revenue of $458.58M in the quarter ending September 30, 2025, with 132.98% growth. This brings the company's revenue in the last twelve months to $1.02B, up 42.11% year-over-year. In the year 2024, Apellis Pharmaceuticals had annual revenue of $781.37M with 97.02% growth.
Revenue (ttm)
$1.02B
Revenue Growth
+42.11%
P/S Ratio
3.09
Revenue / Employee
$1,431,545
Employees
710
Market Cap
3.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 781.37M | 384.78M | 97.02% |
| Dec 31, 2023 | 396.59M | 321.17M | 425.83% |
| Dec 31, 2022 | 75.42M | 8.86M | 13.31% |
| Dec 31, 2021 | 66.56M | -184.08M | -73.44% |
| Dec 31, 2020 | 250.65M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
APLS News
- 24 days ago - The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN - GlobeNewsWire
- 24 days ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 25 days ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 4 weeks ago - Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years - GlobeNewsWire
- 7 weeks ago - Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call Transcript - Seeking Alpha